Scolaris Content Display Scolaris Content Display

Hormone replacement therapy after surgery for epithelial ovarian cancer

This is not the most recent version

References

Additional references

Benkhadra 2015

Benkhadra K, Mohammed K, Nofal AA, Leon BC, Alahdab F, Faubion S, et al. Menopausal hormone therapy and mortality: a systematic review and meta‐analysis. Journal of Clinical Endocrinology & Metabolism 2015;100(11):4021‐8.

Biglia 2015

Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Gallo M. Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas 2015;82(3):296‐8.

Biliatis 2012

Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. Journal of Obstetrics and Gynaecology 2012;32:321‐5.

Cancer Epidemiology 2015

Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‐analysis of 52 epidemiological studies. Lancet 2015;385:1835‐42.

Deeks 2001

Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London (UK): BMJ Publication Group, 2001.

DerSimonian 1986

DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.

Eeles 1991

Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302(6771):259‐62.

Fleming 2013

Fleming G, Seidman J, Lengyel E. Epithelial ovarian cancer. In: Barakat RR, Berchuck A, Markman M, Randall ME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams & Wilkins, 2013:757‐847.

GLOBOCAN 2013

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available from globocan.iarc.fr, accessed on 6 January 20172013.

Guidozzi 1999

Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999;86(6):1013‐8.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;357:557‐60.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Hopkins 2004

Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology 2004;92(3):827‐32.

Ibeanu 2011

Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology 2011;122(2):447‐54.

Langendam 2013

Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81.

Leeper 2002

Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high‐risk women. Gynecologic Oncology 2002;87(1):52‐6.

Li 2012

Li L, Pan Z, Gao K, Zhang W, Luo Y, Yao Z, et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters 2012;3(1):244‐9.

Li 2015

Li D, Ding C‐y, Qiu L‐h. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology 2015;139(2):355‐62.

Liberati 2009

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.

Lowe 2013

Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecologic Oncology 2013;130(1):107‐14.

Marjoribanks 2012

Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4]

Mascarenhas 2006

Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer 2006;119(12):2907‐15.

Meader 2014

Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.

Michaelson‐Cohen 2009

Michaelson‐Cohen R, Beller U. Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology 2009;21(5):407‐11.

Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.

RevMan 2014 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Schunemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glaziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from handbook.cochrane.org.

Singh 2010

Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65(3):190‐7.

Ursic‐Vrscaj 2001

Ursic‐Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001;8(1):70‐5.

Wen 2013

Wen Y, Huang H, Wu M, Shen K, Pan L. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric 2013;16(6):673‐81.

Zhou 2008

Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology 2008;108(3):641‐51.